

Cover Story
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Anthony Letai sworn in as 18th NCI director
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- Population-based cancer surveillance is a national treasure at risk
- Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research